Hair Loss: Understanding, Prevention, and Treatment

Hair Loss Overview

Hair loss affects approximately 50% of men and 25% of women during their lifetime. The human scalp contains 100,000-150,000 hairs, with 85% in active growth (anagen) phase at any time. Normal shedding is 50-100 hairs daily. Pathological hair loss occurs when loss exceeds growth. Understanding hair cycle physiology guides diagnosis and treatment selection. Hair follicle function depends on complex interactions between genetics, hormones, immune function, and environmental factors.

Types of Hair Loss

Androgenetic Alopecia

Most common form, affecting 70% of men and 40% of women by age 70. Genetic and hormonal factors drive miniaturization of androgen-sensitive hair follicles. In men, typically presents with receding hairline and vertex thinning; in women, diffuse crown thinning with preserved hairline. DHT (dihydrotestosterone), converted from testosterone by 5-alpha reductase, drives follicle miniaturization and shortens anagen phase.

Telogen Effluvium

Acute or chronic shedding (>50-100 hairs daily) due to systemic stress pushing hairs prematurely into telogen (resting) phase. Triggered by surgery, high fever, nutritional deficiency, medications, hormonal changes, or psychological stress. Typically self-limited, resolving 3-6 months after trigger removal. Chronic telogen effluvium may persist >6 months and warrants investigation for underlying causes.

Alopecia Areata

Autoimmune condition causing hair loss in discrete patches. T-cell attack on hair follicles drives sudden-onset, round patches of hair loss. May progress to alopecia totalis (complete scalp hair loss) or alopecia universalis (total body hair loss). Variable course; some patients experience spontaneous regrowth. More common in individuals with atopy or family history of autoimmune disease.

Scarring Alopecia

Permanent hair loss from destruction of hair follicle stem cells. Examples include lichen planopilaris, discoid lupus erythematosus (DLE), and morphea. Characterized by absence of follicles on histology (vs non-scarring alopecia where follicles persist). Early intervention before permanent scarring develops is critical.

Androgenetic Alopecia Mechanism

Genetic susceptibility determines follicle sensitivity to DHT. Androgen receptor gene polymorphisms influence this sensitivity. DHT-sensitive follicles undergo progressive miniaturization: anagen phase shortens from 3-5 years to months, hair diameter decreases, and eventual follicle atrophy occurs. The process is irreversible if untreated for prolonged periods; early intervention prevents permanent hair loss.

Telogen Effluvium Details

Stress-induced premature telogen phase shift affects a synchronized cohort of hairs, causing 2-3 month lag between trigger and maximum shedding (reflecting hair cycle timeline). Diagnosis confirmed by gentle traction test (>3 hairs extracted from gentle pull) and dermoscopy showing telogen hairs (club-shaped root). Most resolve spontaneously within 3-6 months; chronic forms (>6 months) warrant thyroid, iron, zinc, and nutritional assessment.

Proven Treatments

FDA-approved treatments for androgenetic alopecia are limited to minoxidil (topical) and finasteride (oral). Both require indefinite use; stopping treatment results in resumption of hair loss. Combination therapy shows superior efficacy to monotherapy. Response timing: 3-6 months to see improvement; 12 months for maximal benefit. Many patients pursue multiple modalities for optimized results.

Minoxidil (Rogaine)

Topical minoxidil is FDA-approved 2% or 5% solution/foam applied twice daily to scalp. Mechanism of action remains incompletely understood but involves increased blood flow, potassium channel opening, and potential hair follicle growth factor stimulation. Efficacy: 40% of users achieve moderate-to-significant regrowth; 40% achieve minimal growth; 20% show no response. Benefits women and men equally. Increased shedding may occur in weeks 2-4 (shedding old hairs before new growth) - encourage continued use. Results plateau at 12 months. Common side effects include scalp irritation; rare: systemic absorption with topical monotherapy.

Finasteride (Propecia, Proscar)

Oral 5-alpha reductase inhibitor reduces DHT levels by 70%. FDA-approved for male pattern hair loss (1mg daily as Propecia). Higher doses (5mg Proscar) used for benign prostatic hyperplasia. Efficacy: 65% of men achieve slowing of hair loss; 48% achieve moderate hair regrowth. Results require 6-12 months; effects plateau at 12 months. Off-label use in women (especially premenopausal) is controversial and requires adequate contraception due to potential feminization of male fetuses. Side effects: reduced libido (1-2%), erectile dysfunction (1-2%), ejaculation changes (rare). Side effects typically resolve upon discontinuation.

Emerging Treatments

Dutasteride: More potent 5-alpha reductase inhibitor reducing DHT 90%; off-label use shows promise but requires more robust evidence. Low-Level Laser Therapy (LLLT): Mixed evidence; may stimulate hair growth through mitochondrial effects but results modest. Platelet-Rich Plasma (PRP): Autologous growth factors injected into scalp; emerging evidence suggests benefit, particularly combined with minoxidil/finasteride. Requires multiple treatments (monthly x3 minimum). JAK Inhibitors: Show promise for alopecia areata; oral ruxolitinib recently approved. Hair Transplantation: Surgical gold standard for advanced androgenetic alopecia; follicular unit extraction (FUE) increasingly popular over strip harvesting.

Prevention Strategies

• Treat androgenetic alopecia early before permanent follicle loss
• Maintain adequate nutrition: protein, iron, zinc, B vitamins essential for hair growth
• Manage stress through exercise, meditation, counseling
• Avoid excessive heat styling, tight hairstyles causing traction alopecia
• Gentle hair care: use wide-tooth comb, avoid harsh treatments
• Address medical conditions (thyroid disease, anemia) affecting hair growth
• Review medications; some cause telogen effluvium (beta-blockers, retinoids, anticoagulants)
• Consider combination therapy for optimal efficacy